PeptidePedia The community reference

Vial (revision 4)

Old revision·14:06, 30 Jul 2024·Areapercent_Ayo

This is an old revision of this page, as it stood at 14:06, 30 Jul 2024, saved by Areapercent_Ayo with the summary expand §Container closure integrity. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Vial
FunctionPrimary container for injectable and lyophilised products
Usual materialType I borosilicate glass
ClosureElastomeric stopper with crimped aluminium ferrule
Common neck finishes13 mm and 20 mm
Common sizes for research peptides2R and 6R
Topic infobox · conventions

A vial is a small container, conventionally of glass, closed by an elastomeric stopper retained under a crimped metal ferrule. It is the standard primary package for injectable products and for lyophilised solids, including the great majority of peptides distributed for research use. The vial, its closure and its seal are treated in pharmaceutical practice as a single functional unit — the container closure system — because none of the three performs its function without the others.[1]

The container has three simultaneous duties. It must contain the product without contributing to it, which constrains the chemistry of both glass and elastomer; it must exclude micro-organisms and, for many products, moisture and oxygen, which is a matter of seal integrity rather than of material; and it must permit withdrawal by needle without loss of that integrity, which is why the closure is a penetrable elastomer rather than a screw cap.[2][1]

Construction and materials

[edit]

Pharmaceutical glass vials are produced by two routes with different characteristics.

Tubing-drawn vials are formed by softening a length of drawn borosilicate tubing and shaping the base and neck. Wall thickness is set by the tubing and is thin and uniform; dimensional tolerances are close; and the process is fast, which makes tubing the route for small vials produced in quantity. Because the neck and base are formed by localised heating, the inner surface at those points reaches higher temperatures than elsewhere and is chemically altered, which is the origin of the delamination susceptibility discussed below.[3]

Moulded vials are formed by pressing molten glass in a mould. Walls are thicker and less uniform, tolerances looser, and the vials heavier and more robust. Moulding dominates for larger containers and where mechanical strength matters more than dimensional precision.[4]

Polymer vials of cyclic olefin polymer or copolymer are established for products incompatible with glass or requiring extreme resistance to breakage. They eliminate delamination and alkali leaching, and they permit lower moisture-vapour barrier performance and different extractable profiles — trade-offs rather than improvements. Requirements for plastic packaging systems are set out in USP <661> and its subsidiary chapters.[5]

References

  1. ^ a b United States Pharmacopeia, General Chapter <1207>, "Package Integrity Evaluation — Sterile Products" (informational), with subchapters <1207.1> to <1207.3>. USP–NF, current revision.
  2. ^ United States Pharmacopeia, General Chapter <381>, "Elastomeric Closures for Injections". USP–NF, current revision.
  3. ^ Ennis RD, Pritchard R, Nakamura C, et al. "Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination." Pharmaceutical Development and Technology 6(3):393–405 (2001).
  4. ^ ISO 8362-1:2018, Injection containers and accessories — Part 1: Injection vials made of glass tubing, read with ISO 8362-4:2011, Part 4: Injection vials made of moulded glass. International Organization for Standardization.
  5. ^ United States Pharmacopeia, General Chapter <661>, "Plastic Packaging Systems and Their Materials of Construction". USP–NF, current revision.